Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6564812 | 0.95 | RAB9A (0.48) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL6565909 | 0.92 | MEN1 (0.49) | RAB9AMAPTMEN1KMT2ALMNA | |
| SCHEMBL6711898 | 0.92 | KMT2A (0.49) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL6567726 | 0.92 | MAPT (0.51) | RAB9AGRIK1MAPTKDM4EMEN1 | |
| SCHEMBL6565985 | 0.92 | MAPT (0.46) | RAB9AGRIK1MAPTKDM4EMEN1 | |
| SCHEMBL6566552 | 0.88 | HTR2A (0.46) | RAB9AGRIK1MAPTKDM4EMEN1 | |
| SCHEMBL6565775 | 0.88 | IDO1 (0.45) | RAB9AMAPTKDM4EMEN1KMT2A | |
| SCHEMBL6566945 | 0.88 | IMPDH2 (0.45) | RAB9AMAPTMEN1KMT2ALMNA | |
| SCHEMBL6566004 | 0.88 | RAB9A (0.47) | RAB9AGRIK1MAPTKDM4EMEN1 | |
| SCHEMBL6564666 | 0.86 | MEN1 (0.54) | RAB9AMAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1437344-A1 | BENZENE DERIVATIVES,PROCESS FOR PREPARING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259912-A1 | Benzine derivatives, process for preparing the same and use thereof | HRH4, HRH2, HRH1 | RAB9A 1322/4885GRIK1 816/4885MAPT 4743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.